Portulaca

Portulaca (Portulaca oleracea L.): An Encyclopedic Reference

1. Identity: Botanical Classification, Common Names, and Forms

Botanical and Chemical Identity

Portulaca oleracea L. is a warm-climate, herbaceous succulent annual plant with a cosmopolitan distribution belonging to the Portulacaceae family. It is an annual herbaceous plant with reddish stems and alternate leaves. The accepted botanical name is Portulaca oleracea L., where the species epithet oleracea derives from the Latin for "vegetable garden." The plant's authority, "L.," designates Carl Linnaeus, who formally described it.

Common Names

It is known by the common names garden (common) purslane, Gelang pasir, Little hogweed, Ma Chi Xian, Munyeroo, Pigweed, Portulaca, Pourpier, Purslane, Pusley, Pussly, Rigla, and Sormai. The Chinese traditional medicine designation Ma Chi Xian translates loosely as "horse-tooth amaranth," referencing the leaf shape.

Natural Source and Distribution

The plant is distributed all over the world and easily grows in diverse soil and climatic conditions. It is distributed in many parts of the world, specifically the tropical and subtropical areas, and has been extensively used as a potherb with green or yellow-leaved forms in many countries. It is listed by the World Health Organization as one of the most used medicinal plants, and has been given the term "Global Panacea."

Parts Used and Common Preparations

All aerial parts of the plant are used, including leaves, stems, flowers, and seeds. It is eaten extensively as a potherb and added in soups and salads around the Mediterranean and tropical Asian countries and has been used as a folk medicine in many countries. In scientific research, preparations have included aqueous and hydroalcoholic extracts, powdered seed capsules, standardized syrups, seed oils, and isolated constituent fractions. P. oleracea is indexed in a number of pharmacopoeias, such as the Ayurvedic Pharmacopoeia of India and Pharmacopoeia of the People's Republic of China.

2. Traditional and Historical Use

Greco-Roman Antiquity

Dioscorides (40–90 CE), the father of pharmacology, mentioned medicinal properties of this plant in his pharmacology book De Materia Medica. In De Materia Medica, it was described as an astringent and a remedy for headaches, inflammation of the eyes and other organs, burning of the stomach, erysipelas, disorders of the bladder, numbness of the teeth, excessive sexual desire, burning fevers, worms, dysentery, hemorrhoids, eruptions of blood, and bites.

Traditional Persian and Islamic Medicine

Purslane has been used as a traditional medicine for alleviating a wide spectrum of diseases including gastrointestinal diseases, respiratory problems, liver inflammation, kidneys and bladder ulcers, fevers, insomnia, severe inflammations, and headaches, as documented by Razi and Ibn Sina. Pharmaceutical properties of P. oleracea were mentioned in most prominent medical textbooks including the Canon of Medicine by Avicenna, Al-Hawi by Rhazes, Zakhireh Kharazmshahi by Jorjani, and other Traditional Persian Medicine (TPM) books.

Traditional Chinese Medicine

Chinese folklore described it as a "vegetable for long life," and it has been used for thousands of years in Traditional Chinese Medicine. It is considered cold in nature and sour in taste, and is used to cool the blood, stanch bleeding, clear heat, and resolve toxins. The dried aerial part is indicated for the treatment of fever, dysentery, diarrhoea, carbuncle, eczema, and hematochezia, with a recommended dose of 9–15 g.

Ayurvedic Tradition

Its documented use in ancient medicinal systems such as Ayurveda, Traditional Chinese Medicine, and in Greco-Roman practices points to its long-standing medicinal value. It has been a part of indigenous healthcare systems across the continents.

Broader Ethnobotanical Use

Portulaca oleracea L. is a widespread medicinal plant that is used not only as an edible plant, but also as a traditional medicine for alleviating a wide spectrum of diseases. Many ethnobotanical studies have reported its use against multiple diseases and ailments. Across cultures, specific preparations have included fresh juice applied topically for earache and toothache, fresh leaf poultices for boils and skin infections, and decoctions administered orally for fevers and digestive disorders.

3. Key Constituents and Active Compounds

Overview of Phytochemical Profile

Several constituents have been isolated from P. oleracea, including flavonoids, alkaloids, terpenoids, carotenoids, fatty acids, sterols, polysaccharides, proteins, vitamins, and minerals. Purslane is a rich source of α-linolenic acid, a vital omega-3 fatty acid, along with notable amounts of palmitic, oleic, and stearic acids, ascorbic acid, β-carotene, α-tocopherols, phenolic alkaloids, glutathione, coumarins, flavonoids, polysaccharides, cardiac glycosides, and anthraquinone glycosides.

Fatty Acids (Omega-3 and Other Lipids)

Purslane is considered one of the richest terrestrial sources of omega-3 and omega-6 fatty acids, suggesting its importance for human health. It is particularly important because of the presence of a very high concentration of omega-3 fatty acids, especially α-linolenic acid, gamma-linolenic acid, and linoleic acid, which are not generally synthesized in terrestrial plants. Quantitative data indicate that fresh plant tissue contains approximately 300–400 mg of alpha-linolenic acid per 100 g, along with 12.2 mg of α-tocopherol, 26.6 mg of ascorbic acid, and 1.9 mg of β-carotene.

Flavonoids

Flavonoids are one of the most abundant and important active constituents of P. oleracea. Kaempferol and apigenin have been mainly isolated from the leaf and stem. Luteolin, myricetin, quercetin, genistein, and genistin have been derived from the whole plant. The amount of flavonoids changes in the various sections of the plant. They are highest in the roots, and subsequently in the stems and leaves; apigenin, genistein, genistin, kaempferol, luteolin, myricetin, and quercetin are seven flavonoids found in this plant. Portulacanones A, B, C, and D, as well as 2,2′-dihydroxy-4′,6′-dimethoxychalcone, have been isolated from the aerial parts of P. oleracea.

Alkaloids (Including Oleraceins and Catecholamines)

A significant proportion—approximately 33%—of identified compounds in aerial part extracts correspond to alkaloid compounds, specifically oleraceins. Two new cyclo-dopa amides named oleraceins X and Y have been identified, along with six known ones (oleraceins A, B, C, N, J, and U). The most abundant compounds were phenolic alkaloids (oleraceins), and the main quantified compounds were isocitric and citric acids. The plant also contains catecholamines including noradrenaline, dopamine, and L-dopa, as well as α-amyrin, β-amyrin, and portuloside A. Studies have revealed that compounds such as noradrenaline and dopamine have anti-inflammatory effects.

Betalains

Betalains are alkaloid-derived pigments found in plants of the order Caryophyllales, including purslane. They can be classified into two groups: betacyanins and betaxanthins. Both have been identified in Portulaca oleracea L. and Portulaca grandiflora. Betacyanin isolated from Portulaca oleracea L. has been reported to exhibit a more significant effect than vitamin C in ameliorating cognitive deficits in mice owing to its potent antioxidant activities.

Polysaccharides

The polysaccharide from P. oleracea, tested in type 2 diabetic mice, significantly lowered fasting blood glucose, total cholesterol, and triglyceride levels. Polysaccharides are considered one of the primary bioactive fractions responsible for the plant's metabolic effects.

Vitamins and Minerals

The plant is rich in omega-3 fatty acids, antioxidants, vitamins (A, C, E), and minerals such as phosphorus, potassium, and iron. A detailed breakdown of its nutritional composition reveals a rich content of vitamins A, C, and E, along with essential minerals such as phosphorus, potassium, calcium, silicon, manganese, and copper. This green leafy vegetable is very low in calories (just 16 kcal/100 g) and fats, yet it is rich in dietary fiber, vitamins, and minerals. It is an excellent source of Vitamin A (1,320 IU/100 g, providing 44% of RDA), one of the highest among green leafy vegetables.

4. Established Mechanisms of Action

Anti-inflammatory Pathways

Results indicate that P. oleracea and its constituents show anti-inflammatory and immunomodulatory properties through reduction of inflammatory mediators, including interferon gamma (IFN-γ), interleukin (IL)-10, IL-4, tumor necrosis factor-alpha (TNF-α), and nitric oxide. Extracts of P. oleracea are abundant in polar lipids that effectively inhibit the NF-κB pathway and activate Nrf2 and peroxisome proliferator-activated receptor γ (PPAR-γ). HM-chromanone, extracted from P. oleracea, was found to reduce levels of inflammatory factors and chemokines in a dose-dependent manner. It also inhibited the activation of the MAPK and NF-κB pathways and improved insulin-stimulated glucose uptake.

Antioxidant Mechanisms

Improvement in cytokines' serum levels (IFN-γ, IL-10, and IL-4) and increased IgG and IgM serum levels, as well as reduction of IgE, phospholipase A2, and total protein were demonstrated for P. oleracea. The plant and its constituents also improved oxidative stress by reduction of oxidant markers and increase of antioxidant markers. An aqueous extract of P. oleracea significantly inhibited DNA damage by comet assay in human lymphocytes, suggesting it could prevent oxidative DNA damage probably because of the anti-oxidant components contained in P. oleracea.

Immunomodulatory Mechanisms

Pharmacological review showed that P. oleracea exerts its effects through anti-inflammatory properties and balancing the adaptive and innate immune system. It acts as an immune-modulator and anti-oxidant agent in both inflammatory states by the dominance of Th2 response—such as asthma, cancer, and atopic dermatitis—and evoked Th1 disorders including hepatitis and multiple sclerosis.

Antidiabetic Mechanisms

Preclinical studies on the hypoglycemic activity of P. oleracea indicate that it can increase pancreas beta cell mass, improve insulin resistance and insulin sensitivity index, improve metabolism of lipids, and modulate glucose metabolism. In a mouse model, purslane improved insulin levels and relieved chronic inflammation through the Rho–NF-κB pathway, thus decreasing the concentration of blood glucose.

Neuroprotective Constituents

The presence of catecholamines in purslane supports the neuroprotective properties of the plant. Neuroprotective, antimicrobial, antidiabetic, antioxidant, anti-inflammatory, antiulcerogenic, and anticancer activities have been broadly documented for Portulaca oleracea.

5. Scientific Evidence by Area of Use

5.1 Metabolic Syndrome, Blood Glucose, and Lipid Profile

This is the most extensively studied clinical area for P. oleracea. A 2024 systematic review and meta-analysis of randomized controlled trials examined the effects of purslane supplementation in patients with type 2 diabetes mellitus. Purslane supplementation significantly reduced fasting blood glucose (FBG) levels (WMD: −15.01; 95% CI: −25.31, −4.71; p = 0.004), total cholesterol (WMD: −17.75; 95% CI: −26.06, −9.45; p < 0.001), triglyceride (WMD: −21.30; 95% CI: −32.59, −10.00; p < 0.001), and low-density lipoprotein cholesterol (LDL-C) (WMD: −6.10; 95% CI: −9.52, −2.68; p < 0.001).

At the level of individual trials, an active-controlled trial on patients with type 2 diabetes found that 10 g/day purslane seed consumption for 8 weeks could decrease serum levels of fasting and postprandial blood glucose, and also produced significant decreases in triglycerides, total cholesterol, LDL cholesterol, body weight, and body mass index. However, a cross-over clinical trial on 48 T2DM patients failed to show a complementary effect of 10 g/day purslane seeds on fasting blood glucose, serum insulin level, and insulin resistance score, although the purslane group showed significant decreases in weight, body mass index, serum triglyceride, and systolic blood pressure.

In obese adolescents, a triple-blinded randomized placebo-controlled clinical trial randomly allocated obese adolescent patients to receive one capsule containing powdered P. oleracea seeds (500 milligrams) two times a day for one month, or identical placebo capsules. This trial assessed lipid outcomes in a pediatric population with dyslipidemia. Modern pharmacological studies have proven many traditional uses of P. oleracea, including anti-hyperglycemic and anti-hyperlipidemic, renoprotective, and hepatoprotective effects.

Evidence strength: The systematic review and meta-analysis level provides the strongest available evidence for beneficial effects on glycemia and lipid profiles in T2DM. Results are statistically significant, but important limitations temper the strength of inference: sample sizes are modest; durations are short; and formulations and doses vary (e.g., seed powder 500 mg b.i.d., standardized syrup, 700 mg/day capsules). Evidence in populations without diabetes is weaker and largely preclinical.

5.2 Non-Alcoholic Fatty Liver Disease (NAFLD)

A randomized, double-blind clinical trial enrolled 74 patients with NAFLD who were randomly assigned to receive either 300 mg purslane extract or placebo for 12 weeks. Outcome measures included NF-κB p65 nuclear activity, serum glutathione peroxidase (GPx) activity, and NF-κB p65 gene expression in peripheral blood mononuclear cells. At the end of the study, a significant decrease of NF-κB p65 nuclear activity was observed in the purslane group compared to the placebo group (P = 0.012). However, there was no significant difference between the two groups in terms of NF-κB nuclear activity, serum adiponectin, and GPx.

In a separate randomized, double-blind clinical trial in NAFLD patients, the group receiving Portulaca oleracea showed significant changes in weight, body mass index, fat mass index, and waist circumference compared to placebo (p < 0.001). Blood sugar, lipid profile, liver enzymes (aspartate and alanine transaminase, gamma-glutamyl transferase), and systolic blood pressure were significantly improved in the intervention group (p < 0.05). Inflammatory and oxidative stress indicators also improved significantly (p < 0.05).

Evidence strength: Preliminary to moderate. Existing human RCTs show promise for liver enzyme and inflammatory marker improvement, but studies are short-term and involve small sample sizes.

5.3 Respiratory Disease and Asthma

The effects of P. oleracea and its constituents such as quercetin and kaempferol on animal models of asthma have been shown. Portulaca oleracea and its constituents also showed therapeutic effects on chronic obstructive pulmonary disease and chronic bronchitis in both experimental and clinical studies. A possible bronchodilatory effect was also reported.

At the preclinical level, a study examined the effects of P. oleracea on bronchoalveolar lavage fluid (BALF) levels of total protein (TP), phospholipase A2 (PLA2), and IgE in sensitized rats. Male rats were randomly divided into groups: control, sensitized, and sensitized animals treated with three concentrations of the extract and dexamethasone. Levels of TP, PLA2, and IgE were significantly increased in the sensitized group compared to control. Treatment with all concentrations of the extract resulted in a significant and concentration-dependent reduction in BALF levels of TP, PLA2, and IgE.

This review indicates the therapeutic effect of P. oleracea and its constituents on various lung and allergic disorders, but more clinical studies are required to establish the clinical efficacy of this plant and its constituents on lung and allergic disorders.

Evidence strength: The evidence remains largely animal and in vitro. Human clinical data on asthma are limited; further controlled trials are necessary before conclusions can be drawn.

5.4 Anti-inflammatory and Immunomodulatory Effects

Review of the literature showed that P. oleracea exerts its effects through anti-inflammatory properties and balancing the adaptive and innate immune system. It has pharmacological properties such as analgesic, antibacterial, skeletal muscle-relaxant, wound-healing, anti-inflammatory activity, and radical scavenging. In vitro, Portulaca oleracea extracts significantly reduce lipopolysaccharide (LPS)-induced synthesis of nitric oxide, the production of TNF-α, IL-6, and the expression levels of various transcription factors in murine macrophage cells.

POL extracts exhibit significantly stronger analgesic and anti-inflammatory properties than ibuprofen in mouse studies, and gas chromatography–mass spectrometry analysis revealed that flavonoids, anthraquinones, and terpenoids may play a key role in these effects.

Evidence strength: Well-supported at preclinical (in vitro and animal) levels. Human anti-inflammatory data are limited to surrogate markers observed in metabolic/hepatic trials. Dedicated clinical anti-inflammatory trials are lacking.

5.5 Hepatoprotective Effects

In an animal study using streptozotocin-induced diabetic mice, purslane significantly reduced concentrations of glucose, aspartate aminotransferase, alanine aminotransferase, triglycerides, total cholesterol, IL-6, IL-1β, and TNF-α in serum. Purslane improved insulin levels and relieved chronic inflammation through the Rho–NF-κB pathway, and was found to be an effective approach for liver injury in diabetes. Human data from NAFLD trials (described above) also support hepatoprotective activity at the clinical level.

Evidence strength: Animal data are well-replicated; human RCT data for NAFLD provide early-stage supportive evidence.

5.6 Antioxidant Effects

There are many studies indicating that the protective effects of P. oleracea could be through its antioxidant activity. Betacyanin isolated from Portulaca oleracea L. has been reported to exhibit a more significant effect than vitamin C in ameliorating cognitive deficits in mice due to potent antioxidant activities. In clinical trials of T2DM and NAFLD, oxidative stress markers have been significantly improved in groups receiving purslane.

Evidence strength: Mechanistically well-established; preclinical evidence is robust. Clinical antioxidant data are an adjunct finding of metabolic trials rather than a primary outcome in dedicated trials.

5.7 Anticancer Properties

Bioactive compounds in P. oleracea, including alkaloids, homoisoflavonoids, and cerebrosides, possess in vitro cytotoxic effects against human cancer cell lines. Portulacerebroside A (PCA), a novel cerebroside compound isolated from P. oleracea, reduces the viability of human liver cancer HCCLM3 cells. PCA markedly elevated the percentage of apoptotic cells, the phosphorylation of p38 MAPK and JNK, the release of mitochondrial cytochrome c and AIF to the cytosol, and activation of caspase-9 and caspase-3. Both natural polysaccharides and seed oil fractions have shown promise against diverse tumor types in preclinical settings, while chemical modification strategies such as platinum coordination further enhance their therapeutic potential. Although current evidence is largely preclinical, these findings support continued exploration of P. oleracea-derived compounds as either standalone anticancer agents or adjuvants to conventional chemotherapy.

A clinical study showed the effect of P. oleracea on patients with lung adenocarcinoma. However, such studies remain isolated and have not been replicated in large-scale trials.

Evidence strength: Predominantly preclinical (in vitro and animal). Human clinical oncology evidence is very limited and should be considered preliminary.

5.8 Neuroprotective Effects

The plant has various pharmacological properties including antioxidant, anticancer, antidiabetic, hypocholesterolemic, neuroprotective, hepatoprotective, anti-inflammatory, antimicrobial, wound-healing, and insecticidal properties. Neuroprotection has been attributed in part to the catecholamine content of the plant. Studies in rotenone-induced neurotoxicity models in rats have demonstrated protective effects, and betacyanins have demonstrated antioxidant activity relevant to cognitive function in animal models. Evidence strength: Limited to preclinical (animal) studies; no controlled human clinical trials for neuroprotective endpoints have been published.

5.9 Antimicrobial Activity

Studies showed that P. oleracea has antibacterial effect on drug-resistant bacteria. The highest MIC for P. oleracea leaves was 200 ppm, while the highest MIC for P. oleracea seeds was 100 ppm.

Evidence strength: Evidence is in vitro only. There are no published human clinical trials for antimicrobial applications of purslane.

6. Body Systems and Health Areas of Association

• Endocrine / Metabolic: Glycemic control, insulin sensitivity, lipid profile modification, metabolic syndrome components. Supported by human RCT data and meta-analysis.
• Hepatic: Liver enzyme normalization, anti-inflammatory effects in NAFLD, hepatoprotection in diabetic models. Supported by animal studies and early human RCTs.
• Cardiovascular: Treatment in db/db mice markedly lowered blood glucose, plasma triglyceride, LDL-cholesterol, and systolic blood pressure in diabetic mice, while significantly increasing plasma HDL-cholesterol and insulin level. Human cardiovascular endpoint data are limited.
• Pulmonary / Immune: Bronchodilatory and antiasthmatic effects in animal models; modulation of Th1/Th2 balance; reductions in IgE and PLA2 in asthma models.
• Renal: Renoprotective effects documented in animal models; oxalate-related nephropathy is a documented risk at high intake (see Safety section).
• Neurological: Neuroprotection in animal models mediated by catecholamines and betalains; no human clinical trials completed.
• Musculoskeletal: As a traditional medicinal plant, P. oleracea's rich nutritional and active components show significant promise for treating musculoskeletal disorders. Evidence is primarily preclinical.
• Dermatological / Wound healing: Traditional and preclinical evidence for wound-healing and anti-eczema properties. Some clinical case-series-level evidence for eczema.
• Gastrointestinal: Traditionally used for dysentery, diarrhea, constipation, and gastric ulcer; antiulcerogenic activity noted in preclinical models.

7. Dosage Forms and Reported Dosages

Limited clinical studies are available to provide dosage guidelines, with various dosages and preparations evaluated. The following dosages have been specifically documented in clinical study reports:

• Powdered seed capsules: One capsule containing powdered P. oleracea seeds (500 milligrams) two times a day for one month was used in a randomized trial in obese adolescents.
• Seeds (whole/powdered): 10 g/day purslane seed consumption for 8 weeks was employed in an active-controlled trial in patients with type 2 diabetes. A separate study using 5 g of P. oleracea seeds twice daily compared purslane to metformin in type 2 diabetic subjects.
• Standardized extract capsules: 300 mg purslane extract given for 12 weeks was used in a randomized, double-blind trial in NAFLD patients.
• Traditional Chinese Medicine: The dried aerial part is indicated at a recommended dose of 9–15 g.
• Formulation variability: Formulations and doses vary across clinical studies, for example: seed powder 500 mg b.i.d., standardized syrup, and 700 mg/day capsules.

8. Safety Considerations

General Safety Profile

The safety of P. oleracea has been reported in many clinical trials. Modern pharmacological studies have now proven many traditional uses of P. oleracea. In many clinical trials, P. oleracea showed no adverse effects, and constipation was reported as the most frequent adverse effect. Overall, purslane appears to be safe and well-tolerated. Its therapeutic effects are associated with fewer and less severe adverse events.

Oxalic Acid Content and Kidney Stone Risk

This is the most clinically significant and source-backed safety concern. Oxalic acid can form insoluble calcium oxalate crystals by binding with calcium, which is associated with a risk of kidney stone formation and other metabolic disorders. Purslane has been regaining its reputation as a valuable food and source of nutrients and biologically active compounds, but a high content of oxalates reduces mineral bioavailability and poses nutritional limitations.

The highest oxalate content was observed in fresh samples (33.38–61.84 g/100 g dry extract), lower in blanched samples (19.07–34.36 g/100 g), and the lowest in pickled samples (10.48–18.31 g/100 g). Raw leaves, stems, and buds have been reported to contain high levels of oxalate and, therefore, are not recommended for regular consumption for people who have a tendency to form kidney stones. Culinary treatments such as blanching and pickling reduced oxalate content.

Oxalate Nephropathy: Clinical Case Evidence

Two cases of acute kidney injury have been reported, considered to be due to oxalate nephropathy in the setting of purslane (Portulaca oleracea) ingestion. The two patients were elderly and presented with oliguria, nausea, vomiting, and clinical manifestations of acute kidney injury requiring renal replacement therapy. One patient underwent an ultrasound-guided renal biopsy, which showed acute tubulointerstitial injury and partial tubular oxalate deposition. Both patients underwent hemodialysis and were discharged following improvement in creatinine levels. A separate case of AKI after eating a large quantity of Portulaca oleracea has been reported, in which renal biopsy confirmed oxalate nephropathy.

A diet high in oxalate can increase the risk of kidney stones and may affect calcium and iron absorption. These case reports are important because they document risk at high-dose or supplement-level intakes, particularly in elderly individuals or those with pre-existing renal vulnerability.

Mineral Absorption Interaction

When present in the human diet, oxalic acid may combine with essential minerals such as calcium and iron, forming insoluble salts known as oxalates and hindering their bioavailability. This is a nutritional interaction rather than a pharmacokinetic drug–drug interaction, but it may be relevant to individuals with calcium or iron deficiencies consuming large quantities of purslane.

Pregnancy and Lactation

Information regarding safety and efficacy in pregnancy and lactation is lacking. An animal study of albino rats dosed with 75 mg/kg/day aqueous or methanolic Portulaca oleracea leaf and stem extract at three different time frames during 21 days of gestation showed no significant differences related to pregnancy stage, fetal development, or delivery. However, as formal human safety data in pregnancy are absent, this should be noted as a data gap.

Potential Drug Interactions

If a patient uses any medicinal plant or has a tendency to use it, they must consult with healthcare providers to prevent drug interactions and adjust the dose of antidiabetic or other drugs. Given the demonstrated blood glucose-lowering and blood pressure-lowering effects documented in human trials, pharmacodynamic interactions with antidiabetic medications (risk of hypoglycemia) and antihypertensives are plausible. Formal contraindications have not been identified in the reviewed clinical literature.

Genotoxicity and Carcinogenicity

Genotoxicity data on Portulaca oleracea-derived ingredients were not found in the published literature, and carcinogenicity data on Portulaca oleracea-derived ingredients were not found in the published literature. The absence of data should not be interpreted as an established safety finding.

9. Pharmacopeial Status and Regulatory Recognition

P. oleracea is indexed in a number of pharmacopoeias such as the Ayurvedic Pharmacopoeia of India and the Pharmacopoeia of the People's Republic of China. It is a well-known plant in European Traditional Medicine. It is listed by the World Health Organization as one of the most used medicinal plants. Formal European Pharmacopoeia, ESCOP, or German Commission E monographs are not currently on record in the reviewed literature.

10. Evidence Summary and Research Gaps

Emerging clinical evidence suggests that Portulaca oleracea can beneficially modulate metabolic, hepatic, dermatologic, and renal outcomes in humans, aligning with its antioxidant and anti-inflammatory pharmacology observed preclinically. The strongest evidence base relates to glycemic control and lipid profile modification in type 2 diabetes, supported by a 2024 systematic review and meta-analysis of randomized controlled trials. Evidence for hepatoprotection, anti-inflammatory activity, respiratory benefits, neuroprotection, and antimicrobial effects remains largely preclinical or relies on small, short-duration human studies.

Collectively, clinical trials—spanning adolescents and adults, and targeting dyslipidemia, eczema, NAFLD, and nephrolithiasis—indicate that P. oleracea is generally well tolerated over 4–8 weeks and can produce measurable improvements in validated surrogate endpoints. The observed benefits are mechanistically congruent with preclinical antioxidant, anti-inflammatory, membrane-stabilizing, and metabolic effects. Longer trials investigating different dosages over longer durations are needed to underpin these findings.

References

• Askari VR et al. (2021). Experimental and clinical studies on the effects of Portulaca oleracea L. and its constituents on respiratory, allergic, and immunologic disorders: a review. PubMed.
• Darvish Damavandi R et al. (2019). A Pharmacological Review on Portulaca oleracea L.: Focusing on Anti-Inflammatory, Anti-Oxidant, Immuno-Modulatory and Antitumor Activities. PMC / Journal of Pharmacopuncture.
• Bioactive compounds and Pharmacological properties of Portulaca oleracea. ScienceDirect, 2026.
• Ghorani V et al. (2023). Phytochemical Characteristics and Anti-Inflammatory, Immunoregulatory, and Antioxidant Effects of Portulaca oleracea L.: A Comprehensive Review. PMC / Evidence-Based Complementary and Alternative Medicine.
• Iranshahy M et al. (2017). A review of traditional uses, phytochemistry and pharmacology of Portulaca oleracea L. Journal of Ethnopharmacology. PubMed.
• Zhou YX et al. (2015). Portulaca oleracea L.: A Review of Phytochemistry and Pharmacological Effects. BioMed Research International / PMC.
• Lee AS et al. (2012). Portulaca oleracea Ameliorates Diabetic Vascular Inflammation and Endothelial Dysfunction in db/db Mice. PMC.
• Movahed A et al. (2014). Clinical Effects of Portulaca Oleracea Seeds on Dyslipidemia in Obese Adolescents: a Triple-blinded Randomized Controlled Trial. PMC.
• Systematic review and meta-analysis: Effects of purslane on C-reactive protein, lipid profile, and glycemic control in T2DM. ScienceDirect, 2024.
• Guo S et al. (2018). Portulaca oleracea L. alleviates liver injury in streptozotocin-induced diabetic mice. PMC.
• Effects of Portulaca oleracea (purslane) on liver function tests, metabolic profile, oxidative stress and inflammatory biomarkers in NAFLD: a randomized, double-blind clinical trial. PMC, 2024.
• Morales M et al. (2021). Phytochemical Composition and Antioxidant Activity of Portulaca oleracea: Influence of the Steaming Cooking Process. PMC.
• Lipophilic Extracts of Portulaca oleracea L.: Analysis of Bioactive Fatty Acids Targeting Microbial and Cancer Pathways. PMC, 2025.
• Pharmacologic Mechanisms of Portulaca oleracea L. in the Treatment of Musculoskeletal Disorders: A Mechanistic Review. PMC, 2025.
• Resilience of Portulaca plants to environmental stresses and the economic potential of their bioactive compounds. Planta / Springer Nature, 2025.
• Review on bioactive phytochemicals and ethnopharmacological potential of purslane (Portulaca oleracea L.). PMC, 2022.
• Modulation of lung inflammation and immune markers in asthmatic rats treated by Portulaca oleracea. PMC.
• Anti-inflammatory effects of the Portulaca oleracea hydroalcoholic extract on human peripheral blood mononuclear cells. PMC.
• Purslane-induced oxalate nephropathy: case report and literature review. BMC Nephrology / Springer Nature, 2023.
• Portulaca oleracea-associated oxalate nephropathy complicated with an ANCA-positive acute renal injury: A case report. ScienceDirect, 2022.
• Assessment of Purslane (Portulaca oleracea L.) Total Oxalate Content, Ascorbic Acid, and Total Organic Acids Using Near-Infrared Spectroscopy. MDPI Plants, 2025.
• Effect of Portulaca oleracea (purslane) extract on inflammatory factors in nonalcoholic fatty liver disease: A randomized, double-blind clinical trial. ScienceDirect, 2023.
• Portulaca oleracea – an overview. ScienceDirect Topics.
• Effects of Portulaca oleracea L. (purslane) on the metabolic syndrome: A review. PMC, 2022.
• Anti-Inflammatory Properties of Extract of the Hairy Root of Native Portulaca oleracea L. and Its Effect on Some Inflammatory Genes Expression in Rat Microglial Cells. PMC, 2024.
• Safety Assessment of Portulaca oleracea-Derived Ingredients. Cosmetic Ingredient Review (CIR), 2020/2022.
• Purslane Extract and Glucose Homeostasis in Adults with Type 2 Diabetes: A Double-Blind, Placebo-Controlled Clinical Trial of Efficacy and Safety. PubMed, 2016.
• Improvement of a Traditional Orphan Food Crop, Portulaca oleracea L. (Purslane) Using Genomics for Sustainable Food Security and Climate-Resilient Agriculture. Frontiers in Sustainable Food Systems, 2021.
• Purslane Uses, Benefits & Dosage. Drugs.com, updated November 2025.